Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia

americanpharmaceuticalreviewMay 28, 2021

Tag: Spruce , tildacerfont , SPR001-202 , ACTH

PharmaSources Customer Service